Lipid Nanoparticles Composed of Quaternary Amine-Tertiary Amine Cationic Lipid Combination (QTsome) for Therapeutic Delivery of AntimiR-21 for Lung Cancer

被引:59
作者
Yung, Bryant C. [1 ]
Li, Jilong [1 ]
Zhang, Mengzi [2 ]
Cheng, Xinwei [3 ]
Li, Hong [1 ]
Yung, Elaine M. [1 ]
Kang, Chen [4 ]
Cosby, Lauren E. [3 ]
Liu, Yang [1 ]
Teng, Lesheng [5 ]
Lee, Robert J. [1 ,2 ,3 ,5 ]
机构
[1] Ohio State Univ, Coll Pharm, Div Pharmaceut, 500 W 12th Ave, Columbus, OH 43210 USA
[2] Ohio State Univ, Mol Cellular & Dev Biol Program, Columbus, OH 43210 USA
[3] Ohio State Univ, Coll Engn, Dept Biomed Engn, Columbus, OH 43210 USA
[4] Ohio State Univ, Coll Pharm, Div Pharmacol, Columbus, OH 43210 USA
[5] Jilin Univ, Coll Life Sci, Changchun 130023, Peoples R China
关键词
nanoparticles; microRNA; cancer; drug delivery; RNA interference; noncoding RNA; gene regulation; PROGNOSTIC VALUE; DRUG-RESISTANCE; EXPRESSION; MIR-21; STABILITY; PCR;
D O I
10.1021/acs.molpharmaceut.5b00878
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
microRNA-21 (miR-21) is an oncomiR that is frequently upregulated in human cancers. AntimiR-21 (AM-21) is an oligonucleotide complementary to miR-21 that is designed to inhibit its gene silencing activities. To facilitate efficient delivery of AM-21, a novel lipid nanoparticle formulation called QTsome, based on a combination of quaternary amine and tertiary amine cationic lipids, with a distinctive pH-responsive profile, was developed. QTsome/AM-21 comprising DODMA/DOTAP/DOPC/CHOL/mPEG-DPPE and AM-21 oligonucleotide exhibited a mean particle diameter of below 150 nm, moderate zeta potential (+13.2 excellent colloidal stability, and high drug loading efficiency (above 80%). In vitro study showed QTsome/AM21 induced upregulation of miR-21 targets, including PTEN and DDAH1, in A549 cells while increasing their sensitivity toward paclitaxel (PTX). Finally, tumor regression, prolonged survival, and miR-21 target upregulation were demonstrated in an A549 xenograft mouse model. These data suggest that QTsome/AM-21 warrants further evaluation as an anticancer agent.
引用
收藏
页码:653 / 662
页数:10
相关论文
共 44 条
[21]   Nanoparticle colloidal stability in cell culture media and impact on cellular interactions [J].
Moore, Thomas L. ;
Rodriguez-Lorenzo, Laura ;
Hirsch, Vera ;
Balog, Sandor ;
Urban, Dominic ;
Jud, Corinne ;
Rothen-Rutishauser, Barbara ;
Lattuada, Marco ;
Petri-Fink, Alke .
CHEMICAL SOCIETY REVIEWS, 2015, 44 (17) :6287-6305
[22]  
Ota T, 2002, ANTICANCER RES, V22, P4049
[23]   Distribution of distant metastases from newly diagnosed non-small cell lung cancer [J].
Quint, LE ;
Tummala, S ;
Brisson, LJ ;
Francis, IR ;
Krupnick, AS ;
Kazerooni, EA ;
Iannettoni, MD ;
Whyte, RI ;
Orringer, MB .
ANNALS OF THORACIC SURGERY, 1996, 62 (01) :246-250
[24]   Analyzing real-time PCR data by the comparative CT method [J].
Schmittgen, Thomas D. ;
Livak, Kenneth J. .
NATURE PROTOCOLS, 2008, 3 (06) :1101-1108
[25]   Interaction of cisplatin, paclitaxel and adriamycin with the tumor suppressor PTEN [J].
Schöndorf, T ;
Becker, M ;
Göhring, UJ ;
Wappenschmidt, B ;
Kolhagen, H ;
Kurbacher, CM .
ANTI-CANCER DRUGS, 2001, 12 (10) :797-800
[26]   Rational design of cationic lipids for siRNA delivery [J].
Semple, Sean C. ;
Akinc, Akin ;
Chen, Jianxin ;
Sandhu, Ammen P. ;
Mui, Barbara L. ;
Cho, Connie K. ;
Sah, Dinah W. Y. ;
Stebbing, Derrick ;
Crosley, Erin J. ;
Yaworski, Ed ;
Hafez, Ismail M. ;
Dorkin, J. Robert ;
Qin, June ;
Lam, Kieu ;
Rajeev, Kallanthottathil G. ;
Wong, Kim F. ;
Jeffs, Lloyd B. ;
Nechev, Lubomir ;
Eisenhardt, Merete L. ;
Jayaraman, Muthusamy ;
Kazem, Mikameh ;
Maier, Martin A. ;
Srinivasulu, Masuna ;
Weinstein, Michael J. ;
Chen, Qingmin ;
Alvarez, Rene ;
Barros, Scott A. ;
De, Soma ;
Klimuk, Sandra K. ;
Borland, Todd ;
Kosovrasti, Verbena ;
Cantley, William L. ;
Tam, Ying K. ;
Manoharan, Muthiah ;
Ciufolini, Marco A. ;
Tracy, Mark A. ;
de Fougerolles, Antonin ;
MacLachlan, Ian ;
Cullis, Pieter R. ;
Madden, Thomas D. ;
Hope, Michael J. .
NATURE BIOTECHNOLOGY, 2010, 28 (02) :172-U18
[27]   microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation [J].
Shen, Yi ;
Tang, Dongfang ;
Yao, Ruyong ;
Wang, Mingzhao ;
Wang, Yongjie ;
Yao, Yasai ;
Li, Xiaoxiao ;
Zhang, Haiping .
MEDICAL ONCOLOGY, 2013, 30 (04)
[28]  
Tam Yuen Yi C, 2013, Pharmaceutics, V5, P498, DOI 10.3390/pharmaceutics5030498
[29]   Lipid Nanoparticles as Carriers for RNAi against Viral Infections: Current Status and Future Perspectives [J].
Torrecilla, Josune ;
Rodriguez-Gascon, Alicia ;
Angeles Solinis, Maria ;
del Pozo-Rodriguez, Ana .
BIOMED RESEARCH INTERNATIONAL, 2014, 2014
[30]  
Ullman-Culleré MH, 1999, LAB ANIM SCI, V49, P319